RT Conference Proceedings
T1 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
A1 Tabernero, J.
A1 Bekaii-Saab, T.
A1 Aguilera, M. Safont
A1 Cubillo, A.
A1 Garcia-Carbonero, R.
A1 Limon, L.
A1 Rodriguez-Salas, N.
A1 Tournigand, C.
A1 Borg, C.
A1 Raghav, K.
A1 Finley, G.
A1 Strickler, J.
A1 Beier, F.
A1 Salim, S.
A1 Esser, R.
A1 Liu, E.
A1 Adrian, S.
A1 Lopez-Lopez, C.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-07-03
LK https://hdl.handle.net/10668/27224
UL https://hdl.handle.net/10668/27224
LA en
DS RISalud
RD Apr 5, 2025